Bibliografía del artículo
1. Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci S, Root RK (eds). Harrison's principles of internal medicine (12th ed), New York: McGraw Hill, 1991.
2. Oberndorfer S. Karzinoid tumoren des dunndarms. Frank Z Pathol 1907; 1:426-429.
3. Gosset A, Masson P. Tumeurs endocrines de l'appendice. Presse Med 1914; 22:237-240.
4. Williams ED, Sandler M. The classification of carcinoid tumors. Lancet 1963; 1:238-239.
5. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813-829.
6. Newton JN, Swerdlow AJ, Dos Santos Silva IM et al. The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994; 70:939-942.
7. Lu Cortez L, Clemente C, Puig V, Mirada A. Carcinoid tumor. An analysis of 131 cases. Rev Clin Esp 1994; 194:291-293.
8. Soga J. Carcinoids of the rectum: An evaluation of 1271 reported cases. Surg Today 1997; 27:112-119.
9. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand [A] 1976; 84:322-330.
10. Zirbes TK, Lorenzen J, Baldus SE et al. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung. Histopathology 1998; 83:123-128.
11. Przygodzki RM, Finkelstein SD, Langer JC et al. Analysis of p53, K-ras-2 and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148:1531-1541.
12. Dong Q, Debelenko LV, Chandrasekharappa SC et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas and other uncommon tumors in subjects with familiar multiple endocrine neoplasia type 1. J Clin Edocrinol Metab 1997; 82(5):1416-1420.
13. Debelenko LV, Brambilla E, Agarwal SK et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997; 6:2285-2290.
14. Brambilla E, Negoescu A, Gazzeri S et al. Apoptosis-related factors p53, bcl2 and bax in neuroendocrine lung tumors. Am J Pathol 1996; 149:1941-1952.
15. Werner P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954; 16:363-371.
16. Sagara M, Sugiyama F, Horiguchi H et al. Activation of the nuclear oncogenes N-myc and c-jun in carcinoid tumors of transgenic mice carrying the human adenovirus type 12 E1 region gene. DNA Cell Biol 1995; 14:95-101.
17. Cheng JY, Sheu LF, Meng CL, Lin JC. Expression of p53 protein in colorectal carcinoids. Arch Surg 1996; 131:67-70.
18. Neary PC, Redmond PH, Houghton T, Watson GR, Bouchier-Hayes D. Carcinoid disease: review of the literature. Dis Colon Rectum 1997; 40:349-362.
19. Azzoni C, Doglioni C, Viale G et al. Involvement of bcl-2 oncoprotein in the development of enterochromaffin like cell gastric carcinoids. Am J Surg Pathol 1996; 20:433-441.
20. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumour. Lancet 1998; 352(9130):799-805.
21. Jakobovitz O, Nass D, DeMarco L et al. Carcinoid tumors frequently display genetic abnormalities involving chromosome 11. J Clin Endocrinol Metab 1996; 81:3164-3167.
22. Walch AK, Zitzelsberger HF, Aubele MM et al. Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol 1998; 153:1089-1098.
23. Debelenko LV, Zhuang Z, Emmert-Buch MR et al. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors. Cancer Res 1997; 57:2238-2243.
24. Tonnies H, Toliat MR, Ramel C et al. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridization. Gut 2001; 48:536-541.
25. Kytola S, Hoog A, Nord B et al. Comparative genomic hybridization identifies less of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 2001; 158:1803-1808.
26. Kytola S, Nord B, Elder EE et al. Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas and abdominal paragangliomas. Genes Chromosomes Cancer 2002; 34:325-332.
27. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status on gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751.
28. Lips CJ, Lentjes EG, Hoppener JW. The spectrum of carcinoid tumours and carcinoid syndromes. Ann Clin Biochem 2003; 40:612-627.
29. Capelli C, Agosti B, Braga M et al. Von Recklinghausen's neurofibromatosis associated with duodenal somatostatinoma. A case report and review of the literature. Minerva Endocrinol 2004; 29:19-24.
30. Mayoral W, Salcedo J, Al-Kawas F. Ampullary carcinoid tumor presenting as acute pancreatitis in a patient with Recklinghausen's disease: care report and review of the literature. Endoscopy 2003; 35:854-857.
31. Vitale L, Lenzi L, Huntsman SA et al. Differential expression of alternatively spliced mRNA forms on the insulin-like growth factor 1 receptor in human neuroendocrine tumors. Oncol Rep 2006; 15: 1249-1256.
32. Van Gompel JJ, Chen H. Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. Surgery 2004; 136:1297-1302.
33. Terris B, Scoazec JY, Rubbia L et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32:133-138.
34. Krishnamurthy S, Dayal Y. Immunohistochemical expressions of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids. Am J Surg Pathol 1997; 21:327-333.
35. Facco C, La Rosa S, Dionigi A, Uccella S, Riva C, Capella C. High expression of growth factors and growth factor receptors in ovarian metastases from ileal carcinoids: an immunohistochemical study of 2 cases. Arch Pathol Lab Med 1998; 122:828-832.
36. Papouchado B, Erickson LA, Rohlinger AL et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18:1329-1335.
37. Chaudhry A, Funa K, Oberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993; 32:107-114.
38. Vikman S, Essand M, Cunningham JL et al. Gene expression in midgut carcinoid tumors: potential targets for immunotherapy. Acta Oncol 2005; 44:32-40.
39. Kidd M, Modlin IM, Mane SM, Camp RL, Eick J, Latich I. The role of genetic markers -NAP1L1, MAGE-D2 and MTA1- in defining small-intestinal carcinoid neoplasia. Ann Surg Oncol 2006; 13:253-262.
40. Saqi A, Alexis D, Remotti F, Bhagat G. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005; 123:394-404.
41. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC. The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 2006; [Epub ahead of print]
42. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch 1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol 2005; 289:G636-642.
43. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004; 1014:13-27.
44. Plockinger U, Rindi G, Arnold R et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 2004; 80:394-424.
45. Rindi G, Azzoni C, La Rosa S et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis. Gastroenterology 1999; 116:532-542.
46. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. WHO International Classification of Tumours, ed. 2. Berlin, Springer, 1999, pp 61-67.
47. Jensen R, Norton J. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT, Hellman S, Rosenberg A, eds. Principles and practice of oncology, 5th ed. Philadelphia, Lippincott, 1996, pp 1704-1723.
48. Kaltsas GA, Bresser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25:458-511.
49. Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J 1995; 71:542-545.
50. Feldman J, Lee E. Serotonin content of foods: effect of urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr 1985; 42:639-643.
51. Degg TJ, Allen KR, Barth JH. Measurement of plasma 5 hydroxyindoleacetic acid in carcinoid disease: an alternative to 24h urine collection. Ann Clin Biochem 2000; 37:724-726.
52. Oberg K. Biochemical diagnosis of neuroendocrine GEP tumor. Yale J Biol Med 1997; 70:501-508.
53. Tomassetti P, Migliori M, Simoni P et al. Diagnostic value of plasma chromographin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13:55-58.
54. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromographin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144:49-59.
55. Eriksson B. Tumor markers for pancreatic endocrine tumors, including chromogranins, HCG-a and HCG-b. In: Mignon M, Jensen R, eds. Endocrine tumors of the pancreas: recent advances in research and management. Basel, Karger, 1995; 121.
56. Watson RW, Schalken JA. Future opportunities for the diagnosis and treatment of prostate cancer. Prostate Cancer Prostatic Dis 2004; 7(Suppl.1):S8-S13.
57. Granberg D, Stridsberg M, Seensalu R et al. Plasma chromographin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999; 84:2712-2717.
58. Janson ET, Holmberg L, Stridsberg M et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8:685-690.
59. Nobels FR, Kwekkeboom DJ, Coopmans W et al. Chromogranin A as serum marker for neuroendocrine neoplasia: a comparison with neuronspecific enolase and the a-subunit of glycoprotein hormones. J Clin Endocr Metab1997; 82:2622-2628.
60. Eriksson B, Arnberg H, Lindgren PG et al. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histological findings in 84 patients. J Intern Med 1990; 228:103-113.
61. Nikou GC, Lygidakis NJ, Toubanakis C et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromographin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005; 52:731-741.
62. Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177:337-341.
63. Kidd M, Modlin IM, Mane SM, Camp RL, Shapiro MD. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg 2006; 243:273-280.
64. Turner GB, Johnston BT, McCance DR et al. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours. Gut 2006; [Epub ahead of print]
65. Lauffer JM, Zhang T, Modlin IM. Current status of gastrointestinal carcinoids. Aliment Pharmacol Ther 1999; 13:271-287.
66. Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol 2005; 100:2307-2314.
67. Dimitroulopoulos D, Xynopoulos D, Tsamakidis K et al. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. W J Gastroenterol 2004; 10:3628-3633.
68. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K et al. The role of Sandostatin in treating patients with advanced hepatocellular carcinoma. Hepatogastroenterology 2002; 49:1245-1250.
69. Krenning EP, Kooij PPM, Bakker WH et al. Radiotherapy with a radiolabelled somatostatin analogue [111 In/DTPA/D/Phe1]-octreotide. Ann NY Acad Sci 1994; 733:496-506.
70. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30:781-793.
71. Lebtahi R, Le Cloirec J, Houzard C et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med 2002; 43:889-895.
72. Schillaci O, Scopinaro F, Angeleti S et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J Nucl Med 1996; 37:1452-1456.
73. Gopinath G, Ahmed A, Buscombe JR, Dickson JC, Caplin ME, Hilson AJ. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging. Nucl Med Commun 2004; 25:253-257.
74. Krausz Y, Keidar Z, Kogan I et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59:565-573.
75. Cwikla JB, Buscombe JR, Caplin ME et al. Diagnostic imaging of carcinoid metastases to the abdomen and pelvis. Med Sci Monit 2004; 10(Suppl.3):9-16.
76. Banzo J, Abos MD, García S et al. Somatostatin receptor scintigraphy. When would a SPECT study be performed? Rev Esp Med Nucl 2003; 22:68-75.
77. Ohrvall U, Westlin JE, Nilsson S et al. Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy. Cancer 1997; 80(Suppl. 12):2490-2494.
78. Virgolini I, Patri P, Novotny C et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001; 12(Suppl. 2):S41-S45.
79. Hanson MW, Feldman JM, Blinder RA, Moore JO, Coleman RE. Carcinoid tumors: Iodine-131 MIBG scintigraphy. Radiology 1989; 172:699-703.
80. Schnirer II, Yao JC, Ajani JA. Carcinoid: A comprehensive review. Acta Oncol 2003; 42:672-692.
81. Le Duc-Pennec A, Thol C, Cavarec M et al. Octreotide imaging plus bone scintigrams to optimally localize gastroenteropancreatic neuroendocrine tumors. Clin Nucl Med 2003; 28:5-8.
82. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112:583-590.
83. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998; 19:641-647.
84. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur Nucl Med 1998; 25:79-83.
85. Orlefors H, Sundin A, Garske U et al. Wholebody (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendodrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90:3392-3400.
86. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D.Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patient with neuroendocrine tumors. Mol Imaging Biol 2003; 5:42-48.
87. Seeman MD, Meisetschlaeger G, Gaa J, Rummeny EJ. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using wholebody PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res 2006; 11:58-65.
88. Chuah SK, Hu TH, Kuo CM et al. Upper gastrointestinal carcinoid tumors incidentally found by endoscopic examinations. World J Gastroenterol 2005; 11:7028-7032.
89. Matsumoto T, Iida M, Suekane H, Tominaga M, Yao T, Fujishima M. Endoscopic ultrasonography in rectal carcinoid tumors: contribution to selection of therapy. Gastrointest Endosc 1991; 37:539-542.
90. Jetmore AB, Ray JE, Gathright JB Jr, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992; 35:717-725.
91. Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy and push enteroscopy in the diagnosis of obscure gastrointestinal bleeding. Chin Med J (Engl) 2004; 117:1045-1049.
92. Coates SW Jr, DeMarco DC. Metastatic carcinoid tumor discovered by capsule encoscopy and not detected by esophagogastroduodenoscopy. Dig Dis Sci 2004; 49:639-641.
93. Hara AK, Leighton JA, Sharma VK, Fleischer DE. Small bowel: preliminary comparison of capsule endoscopy with barium study and CT. Radiology 2004; 230:260-265.
94. Signorelli C, Villa F, Rondonotti E, Abbiati C, Beccari G, de Franchis R. Sensitivity and specificity of the suspected blood identification system in video capsule enteroscopy. Endoscopy 2005; 37:1170-1173.
95. Rosch T, Lightdale CJ, Botet JF et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326:1721-1726.
96. Zimmer T, Ziegler K, Liehr RM, Stolzer U, Riecken EO, Wiedenmann B. Endosonography of neuroendocrine tumors of the stomach, duodenum and pancreas. Ann NY Acad Sci 1994; 33:425-436.
97. Matsushita M, Takakuwa H, Nishio A. Management of rectal carcinoid tumors. Gastrointest Endosc 2003; 58:641-642.
98. Hokama A, Oshiro J, Kinjo F, Saito A. Utility of endoscopic ultrasonography in rectal carcinoid tumors. Am J Gastroenterol 1996; 91:1289-1290.
99. Martínez Ares D, Souto Ruzo J, Varas Lorenzo MJ et al. Endoscopic ultrasound-assisted endoscopic resection of carcinoid tumors of the gastrointestinal tract. Rev Esp Enferm Dig 2004; 96:847-855.